Clinical trials: Sirolimus, completed
Coronary Stenosis
The Impact of Stent Deployment Techniques on Clinical Outcomes of Patient Treated With the CYPHER® Stent (S.T.L.L.R.)
1500 eligible patients will be treated with the commercially available CYPHER® sirolimus-eluting Bx Velocity™ stent. Patients will be followed to twelve months post-procedure, watching for patients that require a repeat procedure…
- Trial name
- NCT00403338
- Testing
- CYPHER® Bx Velocity™ stent (sirolimus-eluting)
- Volunteers
- 1,500 people
- Sponsor
- Cordis US Corp.
Advanced Gastric Cancer, Esophagogastric Junction Cancer
A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy
Adult patients with gastric carcinoma which has progressed after initial treatment with a fluoropyrimidines-containing regimen will be treated with paclitaxel plus RAD001 or plus placebo.
- Trial name
- AIO-STO-0111 (NCT01248403)
- Testing
- Paclitaxel, RAD001
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Krankenhaus Nordwest
Kaposiform Hemangioendothelioma, Kasabach-Merritt Syndrome
Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma
This randomized controlled trial aims to compare guided discontinuation with maintenance treatment of sirolimus in pediatric patients with KHE.
- Trial name
- NCT04448873
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Fudan University
Advanced and Metastatic Silent Neuro-Endocrine Tumors, Carcinoma
RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.
- Conditions
- Advanced and Metastatic Silent Neuro-Endocrine Tumors, Carcinoma, Neuroendocrine, Non Functioning Neuroendocrine Tumors (NETs)
- Trial name
- RAMSETE/CDE16 (NCT00688623)
- Testing
- Everolimus
- Where
- 40 sites in France, Germany and 6 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Brain and Central Nervous System Tumors
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking some of the blood flow to the tumor.
- Trial name
- NCT00553150
- Testing
- everolimus, temozolomide, radiation
- Where
- 178 sites in United States
- Volunteers
- 122 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Highly-sensitized Kidney Transplant Recipients
Role of Everolimus in Highly Sensitized Patients
A growing number of patients on the kidney transplant waiting list are broadly human leukocyte antigen (HLA) sensitized (HS). These patients are unlikely to have a compatible donor.
- Trial name
- NCT01911546
- Testing
- everolimus + low-dose tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Joseph Kahwaji, MD, MPH
Kidney Transplant
Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation
During the past 15 years, however, the superior immunosuppressive efficacy of CsA and the well-known toxicity of long-term steroid therapy have prompted trials of steroid withdrawal from renal allograft recipients at various…
- Trial name
- NCT00309270
- Testing
- Campath-1H
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Breast Cancer
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01031446
- Testing
- cisplatin, everolimus, paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Disorder Related to Cardiac Transplantation
Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation
This study investigated whether initiation of everolimus together with reduction of calcineurin inhibitors (CNI) in maintenance heart or lung transplant patients with renal impairment would improve renal function.
- Trial name
- NOCTET (NCT00377962)
- Testing
- Everolimus, Mycophenolic acid (MPA)/azathioprine (AZA), Calcineurin inhibitors (CNI)
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 282 people
- Sponsor
- Novartis Pharmaceuticals
Brain and Central Nervous System Tumors
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Erlotinib and sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when given…
- Trial name
- NCT00509431
- Testing
- Erlotinib + Sirolimus
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Hypertension, Coronary Artery Disease
Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial
Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was…
- Trial name
- NCT00139386
- Testing
- Candesartan
- Where
- Japan
- Volunteers
- 1,119 people
- Sponsor
- Kumamoto University
Advanced Solid Tumor
Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies
The goal of this study is to determine whether a significant pharmacokinetic interaction exists between rapamycin and sorafenib.
- Trial name
- NCT00449280
- Testing
- Sorafenib, Rapamycin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Chicago
Graft Versus Host Disease, GVHD
Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation
The purpose of this study is to extend the use of Tacrolimus and Sirolimus to determine how effective it is in preventing graft versus host disease (GVHD)in patients that have received non-myeloablative peripheral blood stem cell…
- Trial name
- NCT00282282
- Testing
- tacrolimus, sirolimus, fludarabine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Liver Transplant
Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients.
The purpose of this study is to evaluate the efficacy and safety of CertiroBell® tablet compared with mycophenolate mofetil in primary living donor liver transplant recipients.
- Trial name
- MONTBLANC (NCT04471441)
- Testing
- Everolimus Tab., Mycophenolate mofetil Tab./Cap.
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Malignant Peripheral Nerve Sheath Tumors, MPNST
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
To determine the clinical response rate of everolimus in combination with bevacizumab for patients with chemotherapy refractory sporadic or neurofibromatosis type 1 (NF1) associated malignant peripheral nerve sheath tumor…
- Conditions
- Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma
- Trial name
- NCT01661283
- Testing
- everolimus, bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 25 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Metastatic Renal Cell Carcinoma
RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
To assess whether daily treatment with RAD001 could slow the growth and spread of metastatic carcinoma of the kidney. The safety of RAD001 was also to be studied in this trial.
- Trial name
- RECORD-1 (NCT00410124)
- Testing
- RAD001
- Where
- 93 sites in United States, Australia and 8 more
- Volunteers
- 416 people
- Sponsor
- Novartis Pharmaceuticals
Tuberous Sclerosis, Angiofibroma
Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)
The purpose of this trial is to evaluate the efficacy and safety of NPC-12G gel (topical formulation of sirolimus) versus placebo gel to facial angiofibroma and other skin lesions in patients with tuberous sclerosis complex (TSC)
- Conditions
- Tuberous Sclerosis, Angiofibroma, Hypomelanotic Macule, Plaque
- Trial name
- NCT02635789
- Testing
- NPC-12G gel
- Where
- Japan
- Volunteers
- 62 people
- Sponsor
- Nobelpharma
Ataxia-Telangiectasia (A-T), Ataxia-Telangiectasia
Sirolimus Treatment in Pediatric Patients With Ataxia-Telangiectasia
Ataxia-telangiectasia (A-T) is a progressive disease which is, to date, incurable, affecting motor skills, and a high cancer and recurrent infections risk.
- Trial name
- NCT07820579
- Testing
- Rapamune (sirolimus/rapamycin)
- Where
- Mexico
- Volunteers
- 6 people
- Sponsor
- Sara Elva Espinosa Padilla, MD
Metastatic Renal Cell Carcinoma (mRCC)
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Patients with metastatic renal cell carcinoma (mRCC) who failed first-line therapy with sunitinib or pazopanib was treated with everolimus. Efficacy and safety of everolimus was evaluated in these patients.
- Trial name
- NCT01514448
- Testing
- Everolimus (RAD001)
- Where
- 13 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.